Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Beyond the scavenging of reactive oxygen species (ROS): direct efect of cerium oxide nanoparticles in reducing fatty acids content in an in vitro model of hepatocellular steatosis

  • Parra-Robert, Marina
  • Massana Martinell, Nuria
  • Zeng, Muling
  • Perramón, Meritxell
  • Fernández-Varo, Guillermo
  • Franco Puntes, Victor
  • Casals, Eudald
Cerium oxide nanoparticles; Oxidative stress; Nonalcoholic fatty liver disease, Nanopartículas de óxido de cerio; Estrés oxidativo; Enfermedad del hígado graso no alcohólico, Nanopartícules d’òxid de ceri; Estrès oxidatiu; Malalties hepàtiques no alcohòliques, Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic accumulation of lipids. Antisteatotic effects of cerium oxide nanoparticles (CeO2NPs) have recently been shown in animal models of liver disease. However, it is unclear whether the activity of CeO2NPs is related solely to the decrease in oxidative stress or, in addition, they directly decrease liver fatty acid accumulation. To address this question, in this work, we used an in vitro model of hepatocellular steatosis, exposing HepG2 cells to oleic and palmitic acid. Cell uptake of CeO2NPs and their effect on oxidative stress and viability of hepatic cells cultured with H2O2 were also evaluated. Results show that CeO2NPs were uptaken by HepG2 cells and reduced oxidative stress and improved cell viability. Treatment with oleic and palmitic acid increased lipogenesis and the content of different fatty acids. CeO2NPs reduced palmitic and stearic acid and most fatty acids consisting of more than 18 carbon atoms. These effects were associated with significant changes in elongase and desaturase activity. In conclusion, CeO2NPs directly protected HepG2 cells from cell injury in oxidative stress conditions and reduced fatty acid content in steatotic conditions by inducing specific changes in fatty acid metabolism, thus showing potential in the treatment of NAFLD., This research was funded by Ministerio de Economía y Competitividad, grant number PI15-00077 to G.C. and SAF2016-75358-R to M.M-R., co-financed by FEDER, European Union, “A way of making Europe”.; “Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya, convocatòria d’Indústria del Coneixement modalitat B”, grant number 2018_PROD_00187 toW.J, cofinanced by the European Union through the European Regional Development Fund (ERDF), “A way of making Europe”.; CIBERehd is financed by the Instituto de Salud Carlos III.;Wuyi University Funding for Hight Talents Introduction, grant number 2018TP010 to E.C. and 2018TP011 to M.Z.; Foundation from Department of Education of Guangdong Province, grant number 2016KCXTD005 and 2017KSYS010, to E.C. and M.Z. The APC was funded by Wuyi University Funding for Hight Talents Introduction, grant number 2018TP010 to E.C.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases

  • Casals, Gregori
  • Perramón, Meritxell
  • Portolés, Irene
  • Fernández-Varo, Guillermo
  • Morales-Ruiz, Manuel
  • Franco Puntes, Victor
  • Casals, Eudald
Carcinoma hepatocel·lular; Regeneració hepàtica; Nanocèria, Carcinoma hepatocelular; Regeneración hepática; Nanoceria, Hepatocellular carcinoma; Liver regeneration; Nanoceria, Oxidative stress induced by the overproduction of free radicals or reactive oxygen species (ROS) has been considered as a key pathogenic mechanism contributing to the initiation and progression of injury in liver diseases. Consequently, during the last few years antioxidant substances, such as superoxide dismutase (SOD), resveratrol, colchicine, eugenol, and vitamins E and C have received increasing interest as potential therapeutic agents in chronic liver diseases. These substances have demonstrated their efficacy in equilibrating hepatic ROS metabolism and thereby improving liver functionality. However, many of these agents have not successfully passed the scrutiny of clinical trials for the prevention and treatment of various diseases, mainly due to their unspecificity and consequent uncontrolled side effects, since a minimal level of ROS is needed for normal functioning. Recently, cerium oxide nanoparticles (CeO2NPs) have emerged as a new powerful antioxidant agent with therapeutic properties in experimental liver disease. CeO2NPs have been reported to act as a ROS and reactive nitrogen species (RNS) scavenger and to have multi-enzyme mimetic activity, including SOD activity (deprotionation of superoxide anion into oxygen and hydrogen peroxide), catalase activity (conversion of hydrogen peroxide into oxygen and water), and peroxidase activity (reducing hydrogen peroxide into hydroxyl radicals). Consequently, the beneficial effects of CeO2NPs treatment have been reported in many different medical fields other than hepatology, including neurology, ophthalmology, cardiology, and oncology. Unlike other antioxidants, CeO2NPs are only active at pathogenic levels of ROS, being inert and innocuous in healthy cells. In the current article, we review the potential of CeO2NPs in several experimental models of liver disease and their safety as a therapeutic agent in humans as well., Researches referred by the authors were funded by Fundació La Marató de TV3 (grant Marató 120930), Dirección General de Investigación Científica y Técnica (SAF15-64126-R and RTI2018-094734-B-C21, PID2019-105502RB, and BES-2017-08023), Agència de Gestió d’Ajuts Universitaris i de Recerca (SGR 2017/2019), and Instituto de Salud Carlos III (FIS PI15-00077 and FIS PI19-00774) co-financed by FEDER, European Union, “A way of making Europe” and the National Natural Science Foundation of China (31950410536). The Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is funded by the Instituto de Salud Carlos III.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Functionalized cerium oxide nanoparticles mitigate the oxidative stress and proinflammatory activity associated to the portal vein endothelium of cirrhotic rats

  • Ribera, Jordi|||0000-0002-0288-4220
  • Rodríguez Vita, Juan
  • Cordoba, Bernat
  • Portolés, Irene
  • Casals, Gregori|||0000-0002-3271-1371
  • Casals, Eudald|||0000-0002-2900-7295
  • Jiménez, Wladimiro|||0000-0002-9376-0214
  • Puntes, Víctor|||0000-0001-8996-9499
  • Morales Ruiz, Manuel|||0000-0002-9074-2272
Background and aims- The occurrence of endothelial alterations in the liver and in the splanchnic vasculature of cirrhotic patients and experimental models of liver diseases has been demonstrated. However, the pathological role of the portal vein endothelium in this clinical context is scarcely studied and, therefore, deserves attention. In this context, we aimed to investigate whether pathological endothelial activation occurs in the portal vein of cirrhotic rats. Methods- Cirrhosis was induced in wistar rats by CCl inhalation. We generated immortalized endothelial cells from the portal vein of control (CT-iPVEC) and cirrhotic rats (CH-iPVEC) by retroviral transduction of the SV40 T antigen. We assessed differential gene expression and intracellular reactive oxygen species (ROS) levels in iPVECs and in portal veins of control and cirrhotic rats. Finally, we assessed the therapeutic effectiveness of cerium oxide nanoparticles (CeONP) on reversing PVEC activation and macrophage polarization. Results- CH-iPVECs overexpressed collagen-I, endothelin-1, TIMP-1, TIMP-2, IL-6 and PlGF genes. These results were consistent with the differential expression showed by whole portal veins from cirrhotic rats. In addition, CH-iPVECs showed a significant increase in intracellular ROS and the capacity of potentiating M1 polarization in macrophages. The treatment of CH-iPVECs with CeONPs blocked intracellular ROS formation and IL-6 and TIMP-2 gene overexpression. In agreement with the in vitro results, the chronic treatment of cirrhotic rats with CeONPs also resulted in the blockade of both ROS formation and IL-6 gene overexpression in whole portal veins. Conclusions- Endothelial cells from portal vein of cirrhotic rats depicted an abnormal phenotype characterized by a differential gene expression and the induction of M1 polarization in macrophages. We identified the excess of intracellular reactive oxygen species (ROS) as a major contributor to this altered phenotype. In addition, we demonstrated the utility of the nanomaterial cerium oxide as an effective antioxidant capable of reverse some of these pathological features associated with the portal vein in the cirrhosis condition.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Beyond the scavenging of reactive oxygen species (Ros), direct effect of cerium oxide nanoparticles in reducing fatty acids content in an in vitro model of hepatocellular steatosis

  • Parra-Robert, Marina
  • Casals, Eudald|||0000-0002-2900-7295
  • Massana, Núria|||0000-0002-5403-3161
  • Zeng, Muling
  • Perramón, Meritxell|||0000-0002-1944-8337
  • Fernández-Varo, Guillermo|||0000-0002-7776-3300
  • Morales Ruiz, Manuel|||0000-0002-9074-2272
  • Puntes, Víctor|||0000-0001-8996-9499
  • Jiménez, Wladimiro|||0000-0002-9376-0214
  • Casals, Gregori|||0000-0002-3271-1371
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic accumulation of lipids. Antisteatotic effects of cerium oxide nanoparticles (CeO₂NPs) have recently been shown in animal models of liver disease. However, it is unclear whether the activity of CeONPs is related solely to the decrease in oxidative stress or, in addition, they directly decrease liver fatty acid accumulation. To address this question, in this work, we used an in vitro model of hepatocellular steatosis, exposing HepG2 cells to oleic and palmitic acid. Cell uptake of CeO₂NPs and their effect on oxidative stress and viability of hepatic cells cultured with H₂O₂ were also evaluated. Results show that CeO₂NPs were uptaken by HepG2 cells and reduced oxidative stress and improved cell viability. Treatment with oleic and palmitic acid increased lipogenesis and the content of different fatty acids. CeO₂NPs reduced palmitic and stearic acid and most fatty acids consisting of more than 18 carbon atoms. These effects were associated with significant changes in elongase and desaturase activity. In conclusion, CeO₂NPs directly protected HepG2 cells from cell injury in oxidative stress conditions and reduced fatty acid content in steatotic conditions by inducing specific changes in fatty acid metabolism, thus showing potential in the treatment of NAFLD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Bespoken Nanoceria, An Effective Treatment in Experimental Hepatocellular Carcinoma

  • Fernández-Varo, Guillermo|||0000-0002-7776-3300
  • Perramón, Meritxell|||0000-0002-1944-8337
  • Carvajal, Silvia
  • Oró, Denise
  • Casals, Eudald|||0000-0002-2900-7295
  • Boix, Loreto|||0000-0002-6015-3901
  • Oller, Laura
  • Macías-Muñoz, Laura
  • Marfà, Santi
  • Casals, Gregori|||0000-0002-3271-1371
  • Morales Ruiz, Manuel|||0000-0002-9074-2272
  • Casado, Pedro|||0000-0002-4207-9349
  • Rodríguez Cutillas, Pedro|||0000-0002-3426-2274
  • Bruix, Jordi|||0000-0002-9826-0753
  • Navasa, Miquel|||0000-0002-3130-9604
  • Fuster, Josep
  • García-Valdecasas, Juan Carlos
  • Pavel, Mihai C.
  • Puntes, Víctor|||0000-0001-8996-9499
  • Jiménez, Wladimiro|||0000-0002-9376-0214
Despite the availability of new-generation drugs, hepatocellular carcinoma (HCC) is still the third most frequent cause of cancer-related deaths worldwide. Cerium oxide nanoparticles (CeONPs) have emerged as an antioxidant agent in experimental liver disease because of their antioxidant, anti-inflammatory, and antisteatotic properties. In the present study, we aimed to elucidate the potential of CeONPs as therapeutic agents in HCC. HCC was induced in 110 Wistar rats by intraperitoneal administration of diethylnitrosamine for 16 weeks. Animals were treated with vehicle or CeONPs at weeks 16 and 17. At the eighteenth week, nanoceria biodistribution was assessed by mass spectrometry (MS). The effect of CeONPs on tumor progression and animal survival was investigated. Hepatic tissue MS-based phosphoproteomics as well as analysis of principal lipid components were performed. The intracellular uptake of CeONPs by human ex vivo perfused livers and human hepatocytes was analyzed. Nanoceria was mainly accumulated in the liver, where it reduced macrophage infiltration and inflammatory gene expression. Nanoceria treatment increased liver apoptotic activity, while proliferation was attenuated. Phosphoproteomic analysis revealed that CeONPs affected the phosphorylation of proteins mainly related to cell adhesion and RNA splicing. CeONPs decreased phosphatidylcholine-derived arachidonic acid and reverted the HCC-induced increase of linoleic acid in several lipid components. Furthermore, CeONPs reduced serum alpha-protein levels and improved the survival of HCC rats. Nanoceria uptake by ex vivo perfused human livers and in vitro human hepatocytes was also demonstrated. These data indicate that CeONPs partially revert the cellular mechanisms involved in tumor progression and significantly increase survival in HCC rats, suggesting that they could be effective in patients with HCC.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Beyond the scavenging of reactive oxygen species (ROS): direct efect of cerium oxide nanoparticles in reducing fatty acids content in an in vitro model of hepatocellular steatosis

  • Parra-Robert, Marina
  • Massana Martinell, Nuria
  • Zeng, Muling
  • Perramón, Meritxell
  • Fernández-Varo, Guillermo
  • Franco Puntes, Victor
  • Casals, Eudald
Cerium oxide nanoparticles; Oxidative stress; Nonalcoholic fatty liver disease, Nanopartículas de óxido de cerio; Estrés oxidativo; Enfermedad del hígado graso no alcohólico, Nanopartícules d’òxid de ceri; Estrès oxidatiu; Malalties hepàtiques no alcohòliques, Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic accumulation of lipids. Antisteatotic effects of cerium oxide nanoparticles (CeO2NPs) have recently been shown in animal models of liver disease. However, it is unclear whether the activity of CeO2NPs is related solely to the decrease in oxidative stress or, in addition, they directly decrease liver fatty acid accumulation. To address this question, in this work, we used an in vitro model of hepatocellular steatosis, exposing HepG2 cells to oleic and palmitic acid. Cell uptake of CeO2NPs and their effect on oxidative stress and viability of hepatic cells cultured with H2O2 were also evaluated. Results show that CeO2NPs were uptaken by HepG2 cells and reduced oxidative stress and improved cell viability. Treatment with oleic and palmitic acid increased lipogenesis and the content of different fatty acids. CeO2NPs reduced palmitic and stearic acid and most fatty acids consisting of more than 18 carbon atoms. These effects were associated with significant changes in elongase and desaturase activity. In conclusion, CeO2NPs directly protected HepG2 cells from cell injury in oxidative stress conditions and reduced fatty acid content in steatotic conditions by inducing specific changes in fatty acid metabolism, thus showing potential in the treatment of NAFLD., This research was funded by Ministerio de Economía y Competitividad, grant number PI15-00077 to G.C. and SAF2016-75358-R to M.M-R., co-financed by FEDER, European Union, “A way of making Europe”.; “Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya, convocatòria d’Indústria del Coneixement modalitat B”, grant number 2018_PROD_00187 toW.J, cofinanced by the European Union through the European Regional Development Fund (ERDF), “A way of making Europe”.; CIBERehd is financed by the Instituto de Salud Carlos III.;Wuyi University Funding for Hight Talents Introduction, grant number 2018TP010 to E.C. and 2018TP011 to M.Z.; Foundation from Department of Education of Guangdong Province, grant number 2016KCXTD005 and 2017KSYS010, to E.C. and M.Z. The APC was funded by Wuyi University Funding for Hight Talents Introduction, grant number 2018TP010 to E.C.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases

  • Casals, Gregori
  • Perramón, Meritxell
  • Portolés, Irene
  • Fernández-Varo, Guillermo
  • Morales-Ruiz, Manuel
  • Franco Puntes, Victor
  • Casals, Eudald
Carcinoma hepatocel·lular; Regeneració hepàtica; Nanocèria, Carcinoma hepatocelular; Regeneración hepática; Nanoceria, Hepatocellular carcinoma; Liver regeneration; Nanoceria, Oxidative stress induced by the overproduction of free radicals or reactive oxygen species (ROS) has been considered as a key pathogenic mechanism contributing to the initiation and progression of injury in liver diseases. Consequently, during the last few years antioxidant substances, such as superoxide dismutase (SOD), resveratrol, colchicine, eugenol, and vitamins E and C have received increasing interest as potential therapeutic agents in chronic liver diseases. These substances have demonstrated their efficacy in equilibrating hepatic ROS metabolism and thereby improving liver functionality. However, many of these agents have not successfully passed the scrutiny of clinical trials for the prevention and treatment of various diseases, mainly due to their unspecificity and consequent uncontrolled side effects, since a minimal level of ROS is needed for normal functioning. Recently, cerium oxide nanoparticles (CeO2NPs) have emerged as a new powerful antioxidant agent with therapeutic properties in experimental liver disease. CeO2NPs have been reported to act as a ROS and reactive nitrogen species (RNS) scavenger and to have multi-enzyme mimetic activity, including SOD activity (deprotionation of superoxide anion into oxygen and hydrogen peroxide), catalase activity (conversion of hydrogen peroxide into oxygen and water), and peroxidase activity (reducing hydrogen peroxide into hydroxyl radicals). Consequently, the beneficial effects of CeO2NPs treatment have been reported in many different medical fields other than hepatology, including neurology, ophthalmology, cardiology, and oncology. Unlike other antioxidants, CeO2NPs are only active at pathogenic levels of ROS, being inert and innocuous in healthy cells. In the current article, we review the potential of CeO2NPs in several experimental models of liver disease and their safety as a therapeutic agent in humans as well., Researches referred by the authors were funded by Fundació La Marató de TV3 (grant Marató 120930), Dirección General de Investigación Científica y Técnica (SAF15-64126-R and RTI2018-094734-B-C21, PID2019-105502RB, and BES-2017-08023), Agència de Gestió d’Ajuts Universitaris i de Recerca (SGR 2017/2019), and Instituto de Salud Carlos III (FIS PI15-00077 and FIS PI19-00774) co-financed by FEDER, European Union, “A way of making Europe” and the National Natural Science Foundation of China (31950410536). The Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is funded by the Instituto de Salud Carlos III.